Anti-Galectin-9 Antibody, Neutralizing, clone 9S2-1

Evaluated by Western Blotting in Jurkat cell lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected Galectin-9 in 10 µg of Jurkat cell lysate.

Anti-Galectin-9 Antibody, Neutralizing, clone 9S2-1 is an antibody against Galectin-9 for use in Western Blotting, Neutralizing.

Neutralizing Analysis: A representative lot, when added (10 μg/mL) one hour prior to galectin-9 (10 μg/mL), greatly inhibited galectin-9-induced differenation of cultured human CD14+ PBMCs into dendritic cells (DCs) as assessed by the surface expression of CD40, CD54, and CD80 (Dai, S.Y., et al. (2005). J. Immunol. 175(5):2974-2981).

Research Category
Cell Structure

Research Sub Category
Adhesion (CAMs)

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Galectin-9 (UniProt O00182; also known as Ecalectin, Gal-9, Tumor antigen HOM-HD-21, Urate transporter/channel protein) is encoded by the LGALS9 (also known as HUAT, LGALS9A) gene (Gene ID 3965) in human. The beta-galactoside-binding lectin Galectin-9 possesses two distinct carbohydrate recognition domains (CRDs) linked together by a peptide domain of different length among the S, M, and L spliced isoforms. Galectin-9 plays a key role in a negative feed-back mechanism against Th1 immune response, where galectin-9 production from various cell types (e.g. fibroblasts and endothelial cells) is induced by interferon-gamma produced by CD4+ Th1 lymphocytes. The upregulated galectin-9 in turn suppresses CD4+ Th1 lymphocytes, at least in part through stimulation of the Tim-3 receptor. The Tim-3 receptor on CD4+ Th1 cells from patients with multiple sclerosis (MS), rheumatoid arthritis, and auto-immune hepatitis is defective in its response to galectin-9. In addition, excessive galectin-9 production is reported in two human diseases associated with oncogenic viruses, nasopharyngeal carcinomas (NPC) associated with the Epstein-Barr virus (EBV) and chronic infection by the hepatitis C virus (HCV).

~36/39 kDa observed

Recombinant protein corresponding to human Galectin-9.

Concentration: Please refer to lot specific datasheet.

Format: Purified

Protein G Purified

Purified mouse monoclonal IgG1κ antibody in PBS without preservatives.

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.